StockData
Syndax Pharmaceuticals Inc logo

Syndax Pharmaceuticals Inc (SNDX) stock

SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 3/30
$9.20+0.07 (+0.77%)

Close on Nov 17, 2026Market cap $821.53MP/E –Yield –

Syndax Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Syndax Pharmaceuticals's price to sales ratio was 3.4× on Nov 11, 2026, against 15.4× a year earlier. Over the last 5 years it ranged from 3.4× to 499.2×, with a median of 59.1×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 20263.4×−13.0
2025Dec 31, 202516.4×−54.3
2024Dec 31, 202470.7×+64.1
2022Apr 29, 20226.6×−72.5
2021Dec 31, 202179.1×−362.9
2020Oct 30, 2020442.0×+284.9
2019Dec 31, 2019157.1×+111.1
2018Dec 31, 201845.9×−114.3
2017Dec 29, 2017160.2×+53.4
2016Dec 30, 2016106.8×–

More Syndax Pharmaceuticals figures

See a number that looks wrong?